RxDoctor Payments Data

Wynetta Fletcher, APRN

Family · Morehead, KYNPI 1720070048

Payments from drug & device makers

$411in general payments, 2019–2025

Across 11 payments — averaging $37.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$117
  • Biohaven Pharmaceutical Holding Company Ltd.$111
  • Abbott$47
  • Dexcom, Inc.$25
  • Otsuka America Pharmaceutical, Inc.$22
  • Novartis$21
  • plus $69 from 5 others

What the payments were for

  • Food & beverage$411100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$411 in reported general payments places this provider in the 45th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$14,748
Medicare patients
43
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$46,363
JanuviaSitagliptin Phosphate41$32,170
TrulicityDulaglutide22$30,544
EliquisApixaban31$23,406
Fiasp FlextouchInsulin Aspart (Niacinamide)17$13,695
FarxigaDapagliflozin Propanediol13$12,532
ArexvyRsvpref3 Antigen/As01e/Pf37$11,702
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$10,746
LinzessLinaclotide13$6,862
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,766
MyrbetriqMirabegron21$4,861
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,528
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,294
Rivastigmine12$3,370
Memantine Hcl31$1,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$16$30,54422 claims
AstraZenecaFarxiga, Breztri Aerosphere$13$19,29824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,374 family providers in Kentucky.

Other family in Morehead

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →